share_log

LadRx (NASDAQ:CYTR) Now Covered by StockNews.com

Defense World ·  Mar 29, 2023 13:34

Stock analysts at StockNews.com assumed coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a report released on Wednesday. The firm set a "hold" rating on the stock.

LadRx Stock Performance

LadRx has a 52-week low of $0.05 and a 52-week high of $0.86. The firm's 50 day moving average price is $0.10.

Get LadRx alerts:

LadRx Company Profile

(Get Rating)

LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor.

Featured Articles

  • Get a free copy of the StockNews.com research report on LadRx (CYTR)
  • After an Earnings Blowout, Is Ciena Stock a Buying Opportunity?
  • Meta Breaks Out Of A Base, Looks Like A Growth Stock Again
  • Here's Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
  • The Bottom Is In For McCormick & Company
  • Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story

Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment